TriSalus Life Sciences (TLSI) Revenue (2022 - 2026)

TriSalus Life Sciences' Revenue history runs 5 years deep, the most recent figure standing at $8.9 million for Q1 2026.

• On a quarterly basis, Revenue fell 2.92% year-over-year to $8.9 million in Q1 2026; TTM through Mar 2026 was $44.9 million, a 39.64% increase from a year earlier, with the FY2025 full-year figure at $45.2 million, up 53.41% from the prior year.
• Revenue fell to $8.9 million in Q1 2026 per TLSI's latest filing, from $13.2 million in the prior quarter.
• Across five years, Revenue topped out at $13.2 million in Q4 2025 and bottomed at $3.0 million in Q1 2023.
• The 5-year median for Revenue is $7.3 million (2024), against an average of $7.3 million.
• Across the five-year window, Revenue jumped 116.39% in 2024 and decreased 2.92% in 2026, its largest moves.
• Year by year, Revenue stood at $3.2 million in 2022, then surged by 77.34% to $5.7 million in 2023, then soared by 44.4% to $8.3 million in 2024, then surged by 59.85% to $13.2 million in 2025, then slumped by 32.61% to $8.9 million in 2026.
• Per Business Quant, the three latest TLSI Revenue figures stand at $8.9 million (Q1 2026), $13.2 million (Q4 2025), and $11.6 million (Q3 2025).